Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
11 déc. 2023 12h00 HE
|
Nurix Therapeutics, Inc.
Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete responses in a heavily...
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
04 déc. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
07 nov. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
02 nov. 2023 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
01 nov. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
12 oct. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Achieved an additional $8 million in research...
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics
07 sept. 2023 07h00 HE
|
Nurix Therapeutics, Inc.
Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells Nurix to receive a $60...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
31 août 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
13 juil. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations ...
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
14 juin 2023 07h00 HE
|
Nurix Therapeutics, Inc.
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated...